Skip to main content
Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.000
+0.105 (5.54%)
At close: Mar 6, 2026, 4:00 PM EST
2.000
0.00 (0.00%)
After-hours: Mar 6, 2026, 4:00 PM EST

Editas Medicine Revenue

Editas Medicine had revenue of $7.54M in the quarter ending September 30, 2025, with 12,265.57% growth. This brings the company's revenue in the last twelve months to $46.38M, down -24.90% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.

Revenue (ttm)
$46.38M
Revenue Growth
-24.90%
P/S Ratio
3.99
Revenue / Employee
$188,549
Employees
246
Market Cap
195.73M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202432.31M-45.81M-58.64%
Dec 31, 202378.12M58.41M296.32%
Dec 31, 202219.71M-5.83M-22.83%
Dec 31, 202125.54M-65.19M-71.85%
Dec 31, 202090.73M70.20M341.93%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Heron Therapeutics 154.90M
Compugen 72.76M
ProQR Therapeutics 18.86M
Cartesian Therapeutics 1.09M
Molecular Partners AG 856.30K
SAB Biotherapeutics 114.70K
NeOnc Technologies Holdings 59.99K
Revenue Rankings

EDIT News

More News